Solana Company - Class A Common Stock (HSDT)
Healthcare › Electromedical & Electrotherapeutic Apparatus
Price History
Feb 9, 2026 — Aug 24, 2026Investment Snapshot
- P/B of 0.77 — trading below book value
- Piotroski F-Score 4/9 — moderate financial health
- Loss-making — negative ROE of -297.4%
- Revenue growing at 1,057% annually
Solana Company - Class A Common Stock (HSDT) is a Healthcare company operating in Electromedical & Electrotherapeutic Apparatus, listed on the NASDAQ , with a market capitalisation of $127 million . Key value metrics: P/B ratio 0.77, Piotroski F-Score 4 out of 9 (moderate financial health) .
Value Score
Key Metrics
Current vs 5-Year Average
Based on 5 years of SEC filingsRevenue & Net Income
Financial Statements
| Metric | FY22 | FY23 | FY24 |
|---|---|---|---|
| Revenue | $X.XB | $X.XB | $X.XB |
| Gross Profit | $X.XB | $X.XB | $X.XB |
| Operating Income | $X.XB | $X.XB | $X.XB |
| Net Income | $X.XB | $X.XB | $X.XB |
| EBITDA | $X.XB | $X.XB | $X.XB |
| Total Assets | $X.XB | $X.XB | $X.XB |
| Total Liabilities | $X.XB | $X.XB | $X.XB |
Solana Company - Class A Common Stock — Fundamental Analysis Summary
On financial health, HSDT shows a moderate Piotroski F-Score of 4/9, and negative return on equity of -297.4% (sector average: -20.1%).
StockPik's composite Value Score for HSDT is 57/100 — an above-average value rating. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.
HSDT reports a high gross margin of 93.4% (sector average: 37.4%) and a negative operating margin of -2,483.9%.
HSDT shows revenue growing at 1,057% year-over-year, with earnings declining at 248%.